Key facts
- EviCure’s last known valuation is $12.4M (Mar 2024).
- It has raised $2.8M; the latest was Early Stage VC in Sep 2025.
- Notable investors include Peregrine Ventures.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for EviCure
- ·The full record, as it builds
Funding rounds
No funding rounds for EviCure are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About EviCure
Developer of extracellular vesicle-based platform technology designed for cancer treatment. The company's platform utilizes AI and human cancer models to design EVs loaded with therapeutic molecules or inherent anti-tumor properties, targeting multiple cancer types and potentially overcoming treatment resistance, patients with a safe, cost-effective, mutation-agnostic, and stage-independent treatment.
- Sector
- Healthcare
- HQ
- Ness Tziyona, Israel
- Founded
- 2023
- Employees
- 5
- Website
- evicure.bio/
- Ownership
- Privately Held (backing)
EviCure doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in EviCure shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on EviCure in its N-PORT filings yet. We sweep new filings monthly.